Article
HC Wainwright & Co. Maintains Buy on Evommune, Raises Price Target to $65
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Evommune (NYSE:EVMN) with a Buy and raises the price target from $35 to $65.
Comments
- No comments yet. Be the first to comment!